A Banner Month: October 2026 Brings a New Approval, Four Practice-Shaping Phase 3 Trials, and a Rewritten Radiation Guideline

From Madrid to Washington, the past month delivered progress for men at nearly every stage of the disease — from the biopsy decision to heavily pretreated metastatic cancer. Here is what happened, what the numbers actually say, and what remains unproven.

IPCSG Newsletter · Research Roundup · Sources current through November 2, 2026

Every autumn the European Society for Medical Oncology (ESMO) Congress produces a crop of prostate cancer news, but October 2026 was unusually rich. The 2026 congress, held in Madrid from October 23 to 27, featured a prostate cancer trial in its Presidential Symposium, three further practice-relevant phase 3 updates, and first-in-human data on several genuinely new classes of drugs.^[10,11,12] On October 26, in the middle of the meeting, the U.S. Food and Drug Administration (FDA) moved a PARP-inhibitor combination into an earlier stage of metastatic disease.^[1,27] The American Society for Radiation Oncology (ASTRO) published an updated guideline endorsing shorter radiation courses,^[28] and the courts saw new patent filings over one of our most widely used drugs.

A Note on New Vocabulary

You will see the FDA using unfamiliar labels in this month's approvals. The agency now writes metastatic androgen pathway modulation–naïve or –sensitive (mAPMN/S) prostate cancer for what most of us know as metastatic hormone-sensitive (mHSPC) or castration-sensitive (mCSPC) disease, and androgen pathway modulation–resistant (mAPMR) for what we have long called castration-resistant (mCRPC).^[30,16] The diseases are the same; only the names have changed. This article uses the familiar terms alongside the new ones.

1. FDA Approves Talazoparib + Enzalutamide for Earlier Metastatic Disease

On October 26, 2026, the FDA approved talazoparib (Talzenna, Pfizer) together with enzalutamide (Xtandi) for adults with metastatic hormone-sensitive prostate cancer whose tumors carry a mutation in a homologous recombination repair (HRR) gene, as detected by an FDA-authorized test.^[1] The same pairing had been approved in 2023 for HRR-mutated castration-resistant disease; this decision moves it to the point of first metastatic diagnosis.^[2] The approved mutations include BRCA1/2 and the non-BRCA HRR genes.^[5]

The evidence is the phase 3 TALAPRO-3 trial, which randomized 599 men to enzalutamide plus either talazoparib (0.5 mg daily) or placebo, all on continuous androgen deprivation therapy (ADT). Radiographic progression-free survival (rPFS) — the time until scans show growth or the patient dies — was the primary endpoint. The median rPFS has not yet been reached with the combination, versus 45.8 months with enzalutamide alone, a 52% reduction in the risk of progression or death (hazard ratio [HR] 0.48; 95% CI 0.36–0.65; p<0.0001). Overall survival data are still immature.^[1,3]

Side effects matter here. In the trial, the most common serious (grade 3 or higher) adverse event was anemia, at 51%, generally handled with dose reductions and supportive care; only 5% stopped talazoparib for it. Patient-reported quality of life, presented at ESMO, showed no clinically meaningful difference between arms, although loss of appetite was somewhat worse with talazoparib for roughly the first 40 weeks.^[4] Labeling warns of myelodysplastic syndrome/acute myeloid leukemia and bone marrow suppression.^[1]

What This Means for Members

Get tested. Eligibility depends on a tumor or blood genomic test. FoundationOne CDx (tissue) and FoundationOne Liquid CDx (blood) are the FDA-approved companion diagnostics.^[1] If you have newly diagnosed metastatic disease and have not had HRR testing, ask why.
Expect blood-count monitoring. Anemia is common and usually manageable, but it requires regular labs.

2. ESMO 2026: Four Phase 3 Trials Worth Knowing

DASL-HiCaP: Darolutamide added to radiation for very high-risk localized disease

The prostate cancer headline of the Presidential Symposium was DASL-HiCaP (ANZUP1801), presented by Dr. Tamim Niazi of McGill University.^[11] This investigator-led trial, run by the University of Sydney and the ANZUP cooperative group, randomized 1,106 men with very high-risk localized disease — or with PSA that persisted or recurred within a year of prostatectomy — to darolutamide (Nubeqa, 600 mg twice daily) or placebo for 96 weeks. Every patient also received 96 weeks of ADT and radiation to the prostate or prostate bed and the pelvic lymph nodes.^[8,9] These were genuinely high-risk men: about three-quarters had Gleason 9–10 disease, and 29% had pelvic node involvement on CT.^[7]

At a median follow-up of 3.8 years, darolutamide reduced the risk of metastasis on conventional imaging or death by 58% (HR 0.42; 95% CI 0.27–0.66; p=0.0001). Four-year metastasis-free survival was 95% with darolutamide versus 88% with placebo, and four-year PSA progression-free survival was 91% versus 83% (HR 0.47).^[6,7] Overall survival, however, was not different yet: 97% versus 95% at four years (HR 0.88; 95% CI 0.49–1.59), and prostate cancer–specific survival was 99% in both groups.^[8] Grade 3 or higher side effects occurred in 43% of the darolutamide group versus 36% on placebo.^[9] Bayer has not announced a regulatory filing timeline.^[29]

PROTEUS: Apalutamide before and after prostatectomy

A prespecified randomized substudy of the phase 3 PROTEUS trial, presented by Dr. Alberto Briganti and published simultaneously in European Urology, enrolled 408 men with high-risk localized or locally advanced disease who planned surgery.^[11] Men received apalutamide (Erleada) plus ADT around the time of prostatectomy or surgery alone. After a median of 37.8 months, event-free survival was markedly better with apalutamide: the median has not been reached, versus 19.1 months with surgery alone (HR 0.38; 95% CI 0.26–0.55). By three years, 35% of the apalutamide group needed further treatment, compared with 68% after surgery alone. Grade 3–4 side effects were more frequent (30.7% vs 21.7%), and overall survival will need longer follow-up.^[10] Note the comparator: the control group received no hormone therapy around surgery, so the trial tells us intensification beats surgery alone, not that it beats every alternative.

PEACE-1: Abiraterone's survival benefit holds at almost eight years

Dr. Karim Fizazi presented long-term results of PEACE-1, which enrolled 1,173 men whose cancer had already spread when it was first diagnosed.^[12,11] At a median follow-up of 7.7 years, adding abiraterone plus prednisone to standard care reduced the risk of death by 25% (HR 0.75; 95% CI 0.65–0.87). Median survival was 4.6 years with standard care, 5.7 years with abiraterone added, and 6.4 years with abiraterone plus radiation to the prostate. Among the 710 men who received ADT plus docetaxel, adding abiraterone (the “triplet”) raised median survival from 4.4 to 6.2 years (HR 0.68), and eight-year survival from 27.1% to 40.3%.^[10] Those are mature, hard-endpoint numbers — the kind we rarely get — and they reinforce the case for intensifying treatment at the time of metastatic diagnosis.

CAPItello-281: An honest update on capivasertib for PTEN-deficient disease

CAPItello-281 tested capivasertib (Truqap) plus abiraterone in 1,012 men with newly diagnosed metastatic hormone-sensitive disease whose tumors lacked the PTEN protein. In an updated analysis, median overall survival was 57.4 months with capivasertib versus 46.5 months with placebo (HR 0.82; 95% CI 0.68–0.99), and rPFS was 35.5 versus 26.0 months. However, the survival result was descriptive and did not cross the prespecified threshold for statistical significance.^[10] In plain terms: encouraging, but not yet proof.

Phase 3 results at a glance (October 2026)
Trial	Setting	Added treatment	Key result	Survival status
TALAPRO-3	HRR-mutated metastatic, hormone-sensitive	Talazoparib + enzalutamide	rPFS HR 0.48	Immature
DASL-HiCaP	Very high-risk localized; radiation	Darolutamide	MFS HR 0.42; 4-yr MFS 95% vs 88%	No difference yet
PROTEUS substudy	High-risk localized; surgery	Apalutamide + ADT	EFS HR 0.38	Longer follow-up needed
PEACE-1	De novo metastatic, hormone-sensitive	Abiraterone	OS HR 0.75 at 7.7 yrs	Significant benefit
CAPItello-281	PTEN-deficient de novo metastatic	Capivasertib	OS 57.4 vs 46.5 mo	Not formally significant

3. New Mechanisms in Early Testing

Several first-in-class drugs reported early results in October. These are small, uncontrolled studies, and early response rates often shrink in larger trials — but they show where the field is headed.

JNJ-6143: A once-daily pill that “locks” two proteins together

Johnson & Johnson presented phase 1 results for JNJ-6143 (formerly HLD-0915), the first drug from its RIPTAC platform, acquired with Halda Therapeutics in December 2025.^[15] The molecule binds both the androgen receptor and a cell-survival protein called BRD4 inside prostate cancer cells, disabling BRD4 and triggering cell death.^[13] As of a September 21 data cutoff, 105 heavily pretreated men with castration-resistant disease had received doses from 12.5 to 150 mg.^[14] At the 50 mg dose, among 16 men with measurable tumors, the confirmed objective response rate in the presentation was 69% (11 of 16), including 13% complete responses, with a median response duration of 11 months.^[13] (J&J's own press release counts 12 of 16, or 75%.^[15]) The 50 mg dose moves into a phase 2 study (NCT07832292).^[15] Sixteen patients is a very small number.

FL-020: Next-generation actinium-225 alpha therapy

Readers of our targeted radionuclide therapy coverage will want to follow FL-020, an actinium-225 PSMA-targeted alpha emitter from Full-Life Technologies. In the ProTACT phase 1 study, 18 men had received 6, 7 or 8 MBq by an October 9 cutoff, and 17 were evaluable for PSA response.^[17] At those doses, 88% achieved a PSA decline of at least 50%, including every patient who had never received lutetium-177 and about three-quarters of those who had. One patient whose cancer had progressed on lutetium therapy had a complete response on PSMA PET after two cycles.^[18] A randomized phase 2 dose-optimization study is planned.^[18]

VIR-5500: A “masked” T-cell engager earns Fast Track

On October 8, Vir Biotechnology announced FDA Fast Track designation for VIR-5500, co-developed with Astellas, for late-line castration-resistant disease.^[19] The drug links PSMA on cancer cells to CD3 on T cells, but is designed to stay inactive (“masked”) until enzymes in the tumor remove the mask — an attempt to avoid the toxicity that has plagued earlier T-cell engagers. In phase 1, patients at the higher doses had a median of four prior therapies; 82% of 17 PSA-evaluable patients had a PSA decline of at least 50%, and 45% of 11 measurable patients had tumor shrinkage. Cytokine release syndrome was mostly grade 1, with no grade 3 events and no neurotoxicity reported.^[20] Phase 3 trials are expected to begin in 2027.^[19]

Read With Caution: Carotuximab

On October 6, Kairos Pharma reported interim phase 2 data showing a median progression-free survival of 17.7 months with carotuximab (ENV-105, an antibody against CD105) plus apalutamide versus 2.0 months with apalutamide alone in men with castration-resistant disease (p=0.0008).^[21] The gap is striking, but the company did not disclose the number of patients per arm, a hazard ratio, confidence intervals or baseline characteristics,^[22] and a 2-month median for the control arm is short. The protocol has been changed to test the drug earlier in the disease.^[21] This is a company announcement, not a peer-reviewed result.

4. Diagnosis: Toward Fewer Unnecessary Biopsies

The FDA granted Fast Track designation to Telix Pharmaceuticals' BiPASS program, which tests gallium-68 PSMA PET together with MRI before a biopsy, to decide who needs one and where to aim the needle.^[23] The company announced the designation on September 30, and it was widely reported in early October. Enrollment in the phase 3 BiPASS trial (NCT07052214) is complete; its co-primary endpoints are the sensitivity and specificity of PSMA PET as an add-on to MRI, and completion is expected in 2027.^[24] The program builds on the PRIMARY2 trial, in which PSMA PET reduced biopsies by 49% in men with equivocal or negative MRI findings and at least one risk factor.^[25] Pre-biopsy PSMA PET remains investigational in the U.S.^[23]

5. Radiation Therapy: Shorter Courses Become the Standard

On October 27, ASTRO published an updated clinical practice guideline on hypofractionated (shorter-course) radiation for localized prostate cancer in Practical Radiation Oncology, replacing its 2018 version. The task force was chaired by Dr. Scott C. Morgan of The Ottawa Hospital Cancer Centre.^[28] Key points:

Moderate hypofractionation (e.g., 20 or 28 treatments) is strongly recommended over conventional ~40-treatment courses for all risk groups, regardless of age, other illnesses, anatomy or urinary function.
Ultrahypofractionation (SBRT, 5 treatments) is now a standard option for low- and intermediate-risk disease, preferably given on non-consecutive days over about two weeks. For high-risk disease it receives only a conditional recommendation based on low-quality evidence.
Fewer than five treatments is not recommended outside a clinical trial.
Men with significant urinary symptoms at baseline may do better with moderate hypofractionation than with SBRT.
Decisions about hormone therapy should be made independently of the choice of schedule.^[28]

The guideline arrives on the heels of the ASTRO Annual Meeting (Boston, September 26–30), whose results were still being digested in early October. Long-term follow-up of the randomized PACE-A trial (123 men, median follow-up about eight years) found that five-fraction SBRT controlled localized cancer about as well as prostatectomy; of seven deaths in the trial, none was from prostate cancer.^[31,32] And long-term NRG/RTOG 0815 results showed that adding short-term ADT to radiation for intermediate-risk disease cut prostate cancer deaths (19 vs 5) but did not improve overall survival, because 422 of the 446 deaths were from other causes.^[33] For many intermediate-risk men, that is a useful reminder that competing health risks shape the value of extra treatment.

6. In the Courts: Generic Xtandi and Proton Coverage

New patent suits

Enzalutamide (Xtandi) is approaching generic competition. Sandoz received final FDA approval for generic enzalutamide tablets on April 20, 2026,^[36] and Lupin received tentative approval in June.^[35] According to published intellectual-property timelines, FDA exclusivity for non-metastatic hormone-sensitive disease with biochemical recurrence runs through November 17, 2026, and a key enzalutamide patent expires August 13, 2027.^[35] In October, Astellas Pharma and the Pfizer-owned Medivation entities, which hold the enzalutamide rights, filed two new Hatch-Waxman (ANDA) patent infringement complaints in the U.S. District Court for the District of New Jersey: against Alembic Pharmaceuticals on October 5 (No. 3:26-cv-12995) and against MSN Laboratories, MSN Pharmaceuticals and Novadoz Pharmaceuticals on October 9 (No. 3:26-cv-13220).^[37,38] The public docket entries do not themselves name the product; given the plaintiffs, enzalutamide is the likely subject. Such suits typically delay, rather than prevent, generic entry. When generics do arrive, out-of-pocket costs for many members on enzalutamide should fall.

Proton therapy settlement closes

The claim deadline in Taylor v. Blue Cross Blue Shield Healthcare Plan of Georgia and Anthem Insurance Companies (M.D. Tenn., No. 3:23-cv-00541) passed on October 10, 2026. The $3,625,000 class settlement resolves allegations that Anthem wrongly denied coverage under ERISA plans for proton beam radiation therapy for prostate cancer; payments are pro rata based on documented out-of-pocket costs.^[39] The court granted final approval on August 21, 2026,^[40] and the settlement is expected to benefit about 140 people.^[41]

7. Other Regulatory Notes

The FDA granted Fast Track designation to nine investigational cancer agents in October, VIR-5500 among them.^[26] For context, the talazoparib approval follows the FDA's July 31 approval of lutetium-177 PSMA (Pluvicto) with hormone therapy for PSMA-positive metastatic hormone-sensitive disease, which nearly doubled the number of men eligible for radioligand therapy.^[34]

The Bottom Line

October's common thread is intensification earlier in the disease, guided by biology. Genomic testing now opens the door to a PARP-inhibitor combination at first metastatic diagnosis; PSMA PET may soon help decide who needs a biopsy; and for high-risk localized disease, adding a modern androgen receptor inhibitor to surgery or radiation substantially delays recurrence. The caution is equally consistent: in DASL-HiCaP, PROTEUS and TALAPRO-3, survival benefits have not yet been shown, and the extra drugs add side effects. PEACE-1 reminds us that survival gains can take seven or more years to measure. Bring these findings to your next appointment, ask whether genomic or PSMA testing applies to you, and ask how any added therapy would change both the length and the quality of your life.

Questions to Bring to Your Doctor

Has my tumor (or blood) been tested for HRR mutations such as BRCA2? If not, should it be?
Is my localized cancer “very high-risk”? Would an androgen receptor inhibitor added to radiation or surgery be appropriate, and what are the side effects?
If I am having radiation, am I a candidate for a shorter course (20–28 treatments, or 5-treatment SBRT)?
Are there clinical trials of new agents (alpha therapy, T-cell engagers, RIPTAC drugs) I qualify for?

Glossary

HR (hazard ratio): Relative risk of an event over time; 0.48 means about 52% lower risk.
rPFS: Radiographic progression-free survival: time until scans show growth, or death.
MFS / EFS: Metastasis-free survival / event-free survival.
PSA50: A PSA decline of at least 50% from baseline.
HRR: Homologous recombination repair, a DNA-repair system; BRCA1/2 are HRR genes.
Fast Track: FDA designation allowing more frequent agency contact and possible rolling review; not an approval.
ANDA: Abbreviated New Drug Application, the route for generic drugs.

Sources

U.S. Food and Drug Administration. “FDA Approves Talazoparib with Enzalutamide for Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer with HRR Gene Mutations.” October 26, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive
Norton A. “FDA Expands Talazoparib Combo Indication in Prostate Cancer.” Medscape, October 26, 2026. https://www.medscape.com/viewarticle/fda-expands-talazoparib-combo-indication-prostate-cancer-2026a10014gv
“FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer.” Pharmacy Times, October 26, 2026. https://www.pharmacytimes.com/view/fda-approves-talazoparib-with-enzalutamide-for-hrr-mutated-metastatic-prostate-cancer
“ESMO 2026: Patient Reported Outcomes in Men with mCSPC and HRR Gene Alterations Receiving Talazoparib + Enzalutamide Versus Placebo + Enzalutamide: Results from the Phase 3 TALAPRO-3 Study.” UroToday, October 2026. https://www.urotoday.com/conference-highlights/esmo-2026/esmo-2026-prostate-cancer/172720-...
“FDA Nod for Pfizer's Talzenna plus Xtandi for Prostate Cancer.” The Pharma Letter, October 27, 2026. https://www.thepharmaletter.com/biotech-news/fda-nod-for-pfizer-s-talzenna-plus-xtandi-for-prostate-cancer
“Darolutamide Plus ADT and Radiotherapy Significantly Improves Metastasis-Free Survival in High-Risk Prostate Cancer.” HMP Global Learning Network, October 2026 (reporting Niazi T, et al. DASL-HiCaP, ESMO Congress 2026, Abstract LBA4). https://www.hmpgloballearningnetwork.com/site/onc/news/darolutamide-plus-adt-and-radiotherapy-significantly-improves-metastasis-free
“Darolutamide Delays Prostate Cancer Spread – ESMO 2026.” EMJ Reviews, October 2026. https://www.emjreviews.com/oncology/news/darolutamide-reduces-metastasis-risk-in-prostate-cancer-esmo-2026/
Orion Corporation. “Darolutamide plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence.” Press release, October 24, 2026. https://view.news.eu.nasdaq.com/view?id=1472400
Bayer AG. “Darolutamide plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58%…” News release 2026-0177e, October 2026; see also “Bayer: Darolutamide with ADT and RT Cuts Metastasis-or-Death Risk 58%,” chemXplore. https://www.bayer.com/media/download/e13c4502-52ce-439a-9403-4b79545fb29b/2026-0177e.pdf; https://chemxplore.com/news/darolutamide-prostate-cancer-metastasis-risk
“ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care.” Targeted Oncology, October 2026 (citing Briganti A, et al. Abstract LBA53; Fizazi K, et al. Abstract LBA56; Fizazi K, et al. Abstract 2215O). https://www.targetedonc.com/view/esmo-2026-new-data-advance-prostate-kidney-and-bladder-cancer-care
“Key Updates in GU Oncology From ESMO 2026.” OncoDaily, October 2026. https://oncodaily.com/genitourinary-oncology/gu-oncology-esmo-2026
“3 Prostate Cancer Results From ESMO 2026 Patients Should Know.” CURE, October 2026. https://www.curetoday.com/view/3-prostate-cancer-results-from-esmo-2026-patients-should-know
“ESMO 2026: Safety and Efficacy of JNJ-6143, a First-in-Class Oral AR-Targeted Regulated Induced Proximity Targeting Chimera…” UroToday, October 2026. https://www.urotoday.com/conference-highlights/esmo-2026/esmo-2026-prostate-cancer/172739-...
Clarke H. “Novel RIPTAC Molecule Shows Promising Activity in Heavily Pretreated mCRPC.” Urology Times, October 28, 2026. https://www.urologytimes.com/view/novel-riptac-molecule-shows-promising-activity-in-heavily-pretreated-mcrpc
Johnson & Johnson. “Johnson & Johnson Reports 75% Tumor Response Rate in Advanced Prostate Cancer with JNJ-6143, a First-in-Class RIPTAC™ Molecule.” Press release, October 25, 2026 (via UroToday). https://www.urotoday.com/conference-highlights/esmo-2026/esmo-2026-press-releases/172776-...
Feldman J. “JNJ-6143 Elicits PSA Responses in Heavily Pretreated mCRPC.” Targeted Oncology, October 30, 2026. https://www.targetedonc.com/view/jnj-6143-elicits-psa-responses-in-heavily-pretreated-mcrpc
Full-Life Technologies. “Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026.” Press release, October 23, 2026. https://www.prnewswire.com/news-releases/full-life-technologies-reports-encouraging-preliminary-phase-1-safety-and-psa-decline-for-fl-020-in-mcrpc-at-esmo-2026-302917477.html
“[225Ac]Ac-FL-020 ProTACT Data at ESMO 2026.” Clinical Trial Vanguard, October 2026. https://www.clinicaltrialvanguard.com/?p=33343
Vir Biotechnology, Inc. “Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer.” Press release, October 8, 2026. https://s203.q4cdn.com/628578897/files/doc_news/Vir-Biotechnology-Announces-...-GAJM1.pdf
“VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC.” CancerNetwork, October 9, 2026. https://www.cancernetwork.com/view/vir-5500-receives-fda-fast-track-designation-for-late-line-metastatic-crpc
“Phase 2 Data Show PFS Benefit With Carotuximab Combo in mCRPC.” Targeted Oncology, October 7, 2026. https://www.targetedonc.com/view/carotuximab-apalutamide-pfs-metastatic-castration-resistant-prostate-cancer
“Kairos Reports 17.7-Month PFS with Carotuximab Combination in Phase II Prostate Cancer Trial.” AllSci, October 2026. https://allsci.com/news/clinical-trials/mcrpc-trial-kairos-pharmas-env-105-plus/
Telix Pharmaceuticals Ltd. “Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging.” ASX announcement, September 30, 2026. https://announcements.asx.com.au/asxpdf/20260930/pdf/074pt60dg5972n.pdf
Clarke H. “FDA Grants Fast Track Designation to Pre-Biopsy 68Ga-PSMA-PET Program.” Urology Times, September 30, 2026. https://www.urologytimes.com/view/fda-grants-fast-track-designation-to-pre-biopsy-68ga-psma-pet-program
Hall J. “FDA Grants Fast Track Designation for Pre-Biopsy Use of PSMA PET and MRI for Prostate Cancer Detection.” Diagnostic Imaging, September 30, 2026. https://www.diagnosticimaging.com/view/fda-fast-track-designation-pre-biopsy-use-psma-pet-mri-prostate-cancer-detection
“Oncology Drugs Fast-Tracked by the FDA in October 2026.” Oncology News Central, 2026. https://www.oncologynewscentral.com/drugs/info/oncology-drugs-fast-tracked-by-the-fda-in-october-2026
“October 2026 Oncology Roundup: New Approvals, Trial Findings Inform Treatment Decisions.” Pharmacy Times, October 2026. https://www.pharmacytimes.com/view/october-2026-oncology-roundup-new-approvals-trial-findings-inform-treatment-decisions
“New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer.” CancerNetwork, October 28, 2026 (citing Morgan SC, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol. Published online October 27, 2026. doi:10.1016/j.prro.2026.09.017). https://www.cancernetwork.com/view/new-astro-guideline-backs-hypofractionated-radiation-in-prostate-cancer
Koshti A. “Bayer's Darolutamide Improves Four-Year Metastasis-Free Survival to 95%.” Pharmacally, October 2026. https://pharmacally.com/?p=26834
Foster T. “Prostate Cancer Treatments: What's Next in the FDA Pipeline.” HealthTree, October 13, 2026. https://healthtree.org/news/10-13-2026-prostate-cancer-updates-whats-next-in-fda-pipeline
“ASTRO 2026: Efficacy of Radical Prostatectomy versus SBRT for Localized Prostate Cancer: Results from an International Phase III Randomized Controlled Trial (PACE-A)” and accompanying discussant report. UroToday, 2026. https://www.urotoday.com/conference-highlights/astro-2026/astro-2026-prostate-cancer/172169-...; https://www.urotoday.com/conference-highlights/astro-2026/astro-2026-prostate-cancer/172170-...
“What Data Should Radiation Oncologists Know From ASTRO 2026?” CancerNetwork, 2026 (citing van As N, et al. PACE-A, ASTRO 2026 Abstract LBA 32). https://www.cancernetwork.com/view/what-data-should-radiation-oncologists-know-from-astro-2026-
“ASTRO 2026: Long-Term Follow-up Results for NRG/RTOG 0815…” UroToday, 2026. https://www.urotoday.com/conference-highlights/astro-2026/astro-2026-prostate-cancer/172102-...
Novartis AG. “FDA Approves Pluvicto for PSMA+ Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)…” Press release, July 31, 2026. https://www.novartis.com/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-...
“FDA Approves Generic Enzalutamide Tablets, Including Higher-Strength Options.” Targeted Oncology, 2026. https://www.targetedonc.com/view/fda-approves-generic-enzalutamide-tablets-including-higher-strength-options
“XTANDI Drug Patent Profile.” DrugPatentWatch, updated October 17, 2026. https://www.drugpatentwatch.com/p/alphasignals/tradename/XTANDI
Astellas Pharma Inc. et al. v. Alembic Pharmaceuticals Ltd. et al., No. 3:26-cv-12995 (D.N.J. filed Oct. 5, 2026) (Complaint, ECF No. 1). Docket via Justia. https://dockets.justia.com/docket/new-jersey/njdce/3:2026cv12995/610064
Astellas Pharma Inc. et al. v. MSN Pharmaceuticals Inc. et al., No. 3:26-cv-13220 (D.N.J. filed Oct. 9, 2026) (Complaint, ECF No. 1). Docket via Justia. https://dockets.justia.com/docket/new-jersey/njdce/3:2026cv13220/610399
“$3.6M+ Anthem Settlement Ends Lawsuit Over Denial of Coverage for Proton Beam Cancer Treatments,” ClassAction.org (Taylor et al. v. Anthem Insurance Companies, Inc. et al., No. 3:23-cv-00541, M.D. Tenn.). https://www.classaction.org/news/taylor-et-al-v.-anthem-insurance-companies-inc.-et-al
“Anthem Proton Beam Therapy Class Action Settlement: $3.625 Million for Denied PBRT Coverage.” Open Class Actions, September 21, 2026. https://openclassactions.com/settlements/blue-cross-blue-shield-georgia-proton-beam-therapy-class-action-settlement.php
“Anthem, Blue Cross Georgia Ink $3.6 Million Cancer Coverage Deal.” Bloomberg Law, May 19, 2026. https://news.bloomberglaw.com/class-action/anthem-blue-cross-georgia-ink-3-6-million-cancer-coverage-deal

The IPCSG does not endorse any treatment or product. This report summarizes publicly available information for educational purposes and is not medical advice. Many results described here are from conference presentations and company announcements that have not yet completed peer review. Discuss all treatment decisions with your physicians.

Search This Blog

Informed Prostate Cancer Patient Support